Spectroscopic Quantification of Surfactants in Solid Lipid Nanoparticles

被引:5
作者
Huang, Zhengwei [1 ]
Wu, Mingjun [1 ]
Ma, Cheng [1 ]
Bai, Xuequn [1 ]
Zhang, Xuejuan [2 ]
Zhao, Ziyu [3 ]
Huang, Ying [1 ]
Pan, Xin [1 ]
Wu, Chuanbin [1 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[2] Guangdong Univ Technol, Inst Biomed & Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou, Guangdong, Peoples R China
关键词
Solid lipid nanoparticles; Surfactant; Ultraviolet-visible; Quantification; Quality control; CYTOTOXICITY; INHIBITION; POLOXAMERS; TWEEN-80; DELIVERY; SAFETY; RAT; SLN;
D O I
10.1007/s12247-019-09379-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective Solid lipid nanoparticles (SLN) mainly consist of lipids and surfactants. However, the toxicity of surfactant cannot be ignored, as the surfactant may cause unexpected side effect. This study established model SLN with different surfactants, Tween 80 (T80) and poloxamer 188 (P188). It was aimed to establish ultraviolet-visible (UV-Vis) spectroscopy methods for quantifying the contents of T80 and P188 in the model SLN. Methods The model SLN were produced by emulsification-precipitation method, and their particle size distribution was analyzed. The calibration curves for the contents of T80 and P188 were established. Surfactants in the model SLN were extracted by ultrasonication, and UV-Vis spectroscopy methods were utilized for quantification of surfactants in SLN. Results The deviation of precision and accuracy in P188 and T80 assay were acceptable, which indicated the method could be employed in sample quantification. Ten minutes was considered as the optimal ultrasonication time. And the contents of P188 and T80 were successfully measured by the established UV-Vis methods. Conclusion The UV-Vis spectroscopy methods were developed for the quantification of T80 and P188 in the model SLN. It is expected that the methods could be extended to more SLN systems and applied for the quantification of other surfactants.
引用
收藏
页码:155 / 162
页数:8
相关论文
共 32 条
[1]  
Arechabala B, 1999, J APPL TOXICOL, V19, P163, DOI 10.1002/(SICI)1099-1263(199905/06)19:3<163::AID-JAT561>3.0.CO
[2]  
2-H
[3]   Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats.: Part II -: Tissue distribution [J].
Bargoni, A ;
Cavalli, R ;
Zara, GP ;
Fundarò, A ;
Caputo, O ;
Gasco, MR .
PHARMACOLOGICAL RESEARCH, 2001, 43 (05) :497-502
[4]   Quantification of unadsorbed protein and surfactant emulsifiers in oil-in-water emulsions [J].
Berton, Claire ;
Genot, Claude ;
Ropers, Marie-Helene .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2011, 354 (02) :739-748
[5]   BEHAVIORAL-EFFECTS OF VEHICLES - DMSO, ETHANOL, TWEEN-20, TWEEN-80, AND EMULPHOR-620 [J].
CASTRO, CA ;
HOGAN, JB ;
BENSON, KA ;
SHEHATA, CW ;
LANDAUER, MR .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1995, 50 (04) :521-526
[6]   Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery [J].
Dhawan, Sanju ;
Kapil, Rishi ;
Singh, Bhupinder .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 63 (03) :342-351
[7]   Lipid-drug-conjugate (LDC) solid lipid nanoparticles (SLN) for the delivery of nicotine to the oral cavity - Optimization of nicotine loading efficiency [J].
Ding, Yuan ;
Nielsen, Kent A. ;
Nielsen, Bruno P. ;
Boje, Niels W. ;
Mueller, Rainer H. ;
Pyo, Sung Min .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2018, 128 :10-17
[8]  
Eiermann HJ, 1981, SKIN MICROBIOLOGY RE, P135
[9]   Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80 [J].
Ellis, AG ;
Crinis, NA ;
Webster, LK .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (01) :81-87
[10]   Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers [J].
Fischer, Sarah Maud ;
Brandl, Martin ;
Fricker, Gert .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2011, 79 (02) :416-422